Daniel Jacoby, MD
Associate Professor AdjunctDownloadHi-Res Photo
Cards
Appointments
Cardiovascular Medicine
Primary
Contact Info
About
Titles
Associate Professor Adjunct
Biography
Dr. Daniel Jacoby specializes in the diagnosis and treatment of heart failure and cardiomyopathy.
Dr. Jacoby is the Founder and Director of the premier Cardiomypathy Program in the region, dedicated to serving the needs of patients, and families, living with the diagnosis of cardiomyopathy. Expert diagnosis and treatment of hypertrophic, dilated, arrhythmogenic and restrictive cardiomyopathies, as well as evaluation for causes of sudden cardiac death, are available through the Cardiomyopathy Program.
Dr. Jacoby has contributed widely to the literature of both heart failure and cardiomyopathy.
He serves as the Clinical Director of Innovation for Yale New Haven Health System. In this role Dr. Jacoby provides clinically oriented leadership for mission aligned bio-tech for internal and external partnerships and investments.
Appointments
Cardiovascular Medicine
Associate Professor AdjunctPrimary
Other Departments & Organizations
- Adult Congenital Heart Program
- Cardiovascular Medicine
- Heart Transplant and Left Ventricular Assist Device Program
- Internal Medicine
- Yale Ventures
Education & Training
- Fellow
- Columbia Presbyterian Hospital (2007)
- Chief Fellow
- Columbia Presbyterian Hospital (2007)
- Resident
- Mount Sinai Hospital (2004)
- Chief Resident
- The Mount Sinai Hospital (2004)
- MD
- Yale School of Medicine (2000)
- BA
- Yale College, Judaic Studies (1993)
Research
Overview
Medical Subject Headings (MeSH)
Amyloidosis; Clinical Trial; Genetics; Heart Failure; Heart Transplantation; Sleep
ORCID
0000-0002-9182-275X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Daniel Jacoby's published research.
Publications Timeline
A big-picture view of Daniel Jacoby's research output by year.
Research Interests
Research topics Daniel Jacoby is interested in exploring.
Sangchoon Jeon, PhD
Tariq Ahmad, MD, MPH
Christopher Maulion, MD
Edward J Miller, MD, PhD
Nancy Schmieder Redeker, RN, MSN, PhD, FAHA, FAAN
Harlan Krumholz, MD, SM
75Publications
3,875Citations
Heart Failure
Heart Transplantation
Sleep
Amyloidosis
Publications
2024
Efficacy and Safety of aficamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
Masri A, Sherrid M, Abraham T, Choudhury L, Garcia-Pavia P, Kramer C, Barriales-Villa R, Owens A, Rader F, Nagueh S, Olivotto I, Saberi S, Tower-Rader A, Wong T, Coats C, Watkins H, Fifer M, Solomon S, Heitner S, Jacoby D, Kupfer S, Malik F, Meng L, Sohn R, Wohltman A, Maron M, Investigators R. Efficacy and Safety of aficamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4. Journal Of Cardiac Failure 2024 PMID: 38493832, DOI: 10.1016/j.cardfail.2024.02.020.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNonobstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreOpen-label phase 2 trialNew York Heart Association classHistory of aborted sudden cardiac deathNon-obstructive hypertrophic cardiomyopathyHigh-sensitivity cardiac troponin IAborted sudden cardiac deathBlood levels of biomarkersNT-proBNP levelsPhase 2 trialPlacebo-controlled studyHeart failure symptomsCardiac myosin inhibitorClinical summary scoreSudden cardiac deathClinically relevant improvementWeeks of washoutLevels of biomarkersCardiac troponin IHeart muscle cellsAsymptomatic reductionNT-proBNPAssociated with improvementsCardiovascular Hospitalizationspost Septal Myectomy For Obstructive Hypertrophic Cardiomyopathy: A 3-year Analysis Of 5,101 Patients
Altibi A, Elman M, Zhao Y, Chehab J, Butzner M, Heitner S, Jacoby D, Sohn R, Masri A. Cardiovascular Hospitalizationspost Septal Myectomy For Obstructive Hypertrophic Cardiomyopathy: A 3-year Analysis Of 5,101 Patients. Journal Of Cardiac Failure 2024, 30: 199-200. DOI: 10.1016/j.cardfail.2023.10.201.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyIncidence of cardiovascular hospitalizationsSeptal myectomyCardiovascular hospitalizationChronic kidney diseaseChronic obstructive pulmonary diseaseHypertrophic cardiomyopathyPost-SMVentricular arrhythmiasHeart failureCumulative incidence of cardiovascular hospitalizationsFollow-upYears median follow-upMedian follow-upAdvanced HF therapiesHealth claims databaseAdvanced heart failureEmergency department visitsPacemaker/implantable cardioverter defibrillatorObstructive pulmonary diseaseHF therapyAtrial fibrillation/flutterCumulative incidenceCardiac arrestMultivariate regression modelCharacteristics And Procedural Complications Of Septal Myectomy For Obstructive Hypertrophic Cardiomyopathy In The United States
Altibi A, Elman M, Zhao Y, Chehab J, Butzner M, Heitner S, Jacoby D, Sohn R, Masri A. Characteristics And Procedural Complications Of Septal Myectomy For Obstructive Hypertrophic Cardiomyopathy In The United States. Journal Of Cardiac Failure 2024, 30: 177-178. DOI: 10.1016/j.cardfail.2023.10.149.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathySeptal myectomyBaseline characteristicsHypertrophic cardiomyopathyInpatient complicationsConcomitant mitral valve repairVentricular septal defectMitral valve repairMitral valve replacementPredictor of inpatient complicationsCohort of patientsOutcomes of SMValve repairSeptal defectValve replacementAtrial fibrillation/flutterAnoxic brain damagePacemaker implantationAdult patientsHeart blockCardiac arrestEmergency intubationProcedural outcomesContinuous enrollmentMyectomyLong-term Safety And Tolerability Of Acoramidis (AG10) In Symptomatic Transthyretin Amyloid Cardiomyopathy: 4-year Update From An Ongoing, Phase 2, Open-label Extension Study
Masri A, Aras M, Falk R, Grogan M, Jacoby D, Maurer M, Shah S, Witteles R, Wong P, Ji A, Du J, Siddhanti S, Sinha U, Fox J, Judge D. Long-term Safety And Tolerability Of Acoramidis (AG10) In Symptomatic Transthyretin Amyloid Cardiomyopathy: 4-year Update From An Ongoing, Phase 2, Open-label Extension Study. Journal Of Cardiac Failure 2024, 30: 221. DOI: 10.1016/j.cardfail.2023.10.251.Peer-Reviewed Original ResearchConceptsOpen-label extensionATTR-CMAmyloid cardiomyopathyPhase 3 randomized clinical trialMedian NT-proBNP levelOpen-label extension studyNYHA class IIMedian follow-upNT-proBNP levelsPhase 2 studyPhase 2 trialTransthyretin amyloid cardiomyopathyNT-pro-BNPOpen-label studyLong-term treatmentLong-term safetyEx vivo assaysDouble-blindPlacebo-controlledNT-proAdverse eventsFollow-upClinical trialsConcurrent illnessDay 1Baseline Characteristics of Patients in SEQUOIA-HCM: A Phase 3 Trial of Aficamten in Obstructive Hypertrophic Cardiomyopathy
Maron M, Abraham T, Coats C, Olivotto I, Lee M, Arad M, Cardim N, Ma C, Choudhury L, Düngen H, Garcia-Pavia P, Hagege A, Lewis G, Michels M, Oreziak A, Owens A, Tfelt-Hansen J, Veselka J, Watkins H, Heitner S, Jacoby D, Kupfer S, Malik F, Meng L, Wohltman A, Masri A. Baseline Characteristics of Patients in SEQUOIA-HCM: A Phase 3 Trial of Aficamten in Obstructive Hypertrophic Cardiomyopathy. Journal Of Cardiac Failure 2024, 30: s3. DOI: 10.1016/j.cardfail.2023.11.006.Peer-Reviewed Original ResearchConceptsLeft ventricular outflow tract obstructionObstructive hypertrophic cardiomyopathySymptomatic obstructive hypertrophic cardiomyopathyBaseline characteristics of patientsCardiac myosin inhibitorPhase 3 trialCharacteristics of patientsBaseline characteristicsHypertrophic cardiomyopathyNew York Heart Association functional classVentricular outflow tract obstructionN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideTreated with beta-blockersHigh-sensitivity cardiac troponin IBaseline New York Heart Association functional classOutflow tract obstructionPlacebo-controlled trialBaseline to weekHeart failure symptomsIndividual daily doseReduced exercise capacityCardiac troponin IMyocardial hypercontractilityOral placebo
2023
Long term outcome after septal reduction therapies in patients with hypertrophic cardiomyopathy: insights from the SHaRe registry
Maurizi N, Day S, Ashley E, Michels M, Pereira A, Helms A, Saberi S, Jacoby D, Ware J, Colan S, Semsarian C, Ingles J, Ho C, Olivotto I. Long term outcome after septal reduction therapies in patients with hypertrophic cardiomyopathy: insights from the SHaRe registry. European Heart Journal 2023, 44: ehad655.1852. DOI: 10.1093/eurheartj/ehad655.1852.Peer-Reviewed Original ResearchConceptsLong-term outcomesPeri-procedural mortalityAlcohol septal ablationTerm outcomesHF outcomesComposite outcomeLV maximal wall thicknessDilated left atriumSeptal reduction therapyPredictor of prognosisMaximal wall thicknessPost-operative resultsProportional hazards modelMost available studiesLA diameterSeptal ablationVA outcomesHeart failureOverall mortalityLV EFVentricular arrhythmiasHF eventsHCM patientsSarcomeric mutationsSpecialty centers
2022
Correlates of cognition among people with chronic heart failure and insomnia
Geer JH, Jeon S, O’Connell M, Linsky S, Conley S, Hollenbeak CS, Jacoby D, Yaggi HK, Redeker NS. Correlates of cognition among people with chronic heart failure and insomnia. Sleep And Breathing 2022, 27: 1287-1296. PMID: 36214945, PMCID: PMC10084469, DOI: 10.1007/s11325-022-02716-w.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsChronic heart failureHigher body mass indexHeart failureBody mass indexQuality of lifeMass indexDaytime sleepinessNew York Heart Association class ICognitive impairmentSignificant risk factorsNon-white raceSelf-reported cognitive impairmentInsomnia Severity IndexSleep disturbance questionnaireCross-sectional analysisCognitive behavioral therapyFrequency of lapsesMedical comorbiditiesCommon comorbiditiesClinical factorsEjection fractionPulmonary diseaseMultivariable analysisRisk factorsSleep characteristicsThe Yale Roadmap for Health Psychology and Integrated Cardiovascular Care
Gaffey AE, Harris KM, Mena-Hurtado C, Sinha R, Jacoby DL, Smolderen KG. The Yale Roadmap for Health Psychology and Integrated Cardiovascular Care. Health Psychology 2022, 41: 779-791. PMID: 35201804, DOI: 10.1037/hea0001152.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCardiovascular careCardiovascular diseaseHealth care systemRisk factorsBehavioural risk factor managementTraditional atherosclerotic risk factorsWagner's Chronic Care ModelCare systemAtherosclerotic risk factorsRisk factor managementChronic Care ModelCause of morbidityMental health burdenBehavioral risk factorsChronic cardiovascular diseaseHigh-intensity careAdverse health outcomesMental health disordersHealth psychologyEvidence-based approachComplex multimorbidityRisk patientsCardiovascular populationFactor managementChronic diseasesPragmatic randomized trial assessing the impact of digital health technology on quality of life in patients with heart failure: Design, rationale and implementation
Victoria‐Castro A, Martin M, Yamamoto Y, Ahmad T, Arora T, Calderon F, Desai N, Gerber B, Lee KA, Jacoby D, Melchinger H, Nguyen A, Shaw M, Simonov M, Williams A, Weinstein J, Wilson FP. Pragmatic randomized trial assessing the impact of digital health technology on quality of life in patients with heart failure: Design, rationale and implementation. Clinical Cardiology 2022, 45: 839-849. PMID: 35822275, PMCID: PMC9346973, DOI: 10.1002/clc.23848.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsQuality of lifeHF patientsYale New Haven Health SystemKansas City Cardiomyopathy QuestionnaireDigital health technologiesHeart failure careHealth technologiesDigital health interventionsDisease exacerbationHF clinicUsual carePrimary outcomeClinical outcomesHeart failurePatient engagementPatientsHealth interventionsDigital health toolsPatient empowermentHealth systemPatient usabilityHealth toolsEarly detectionFirst enrollmentHealthcare systemImpact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
Gimeno JR, Olivotto I, Rodríguez AI, Ho CY, Fernández A, Quiroga A, Espinosa MA, Gómez‐González C, Robledo M, Tojal‐Sierra L, Day SM, Owens A, Barriales‐Villa R, Larrañaga JM, Rodríguez‐Palomares J, González‐del‐Hoyo M, Piqueras‐Flores J, Reza N, Chumakova O, Ashley EA, Parikh V, Wheeler M, Jacoby D, Pereira AC, Saberi S, Helms AS, Villacorta E, Gallego‐Delgado M, de Castro D, Domínguez F, Ripoll‐Vera T, Zorio‐Grima E, Sánchez‐Martínez J, García‐Álvarez A, Arbelo E, Mogollón MV, Fuentes‐Cañamero M, Grande E, Peña C, Monserrat L, Lakdawala NK, Muñoz‐Esparza C, García‐Pinilla J, Robles‐Mezcua A, Moreno‐Flores M, Peña M, Merlo M, Cubillo D, Climent‐Payá V, Dankovtseva E, Vilela A, García‐Pavía P, Casas G. Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure 2022, 9: 2189-2198. PMID: 36255281, PMCID: PMC9288745, DOI: 10.1002/ehf2.13964.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSARS-CoV-2 infectionVentricular outflow tract obstructionOutflow tract obstructionRisk of mortalityHypertrophic cardiomyopathySARS-CoV-2HCM patientsSystolic impairmentTract obstructionOdds ratioBaseline New York Heart Association classNew York Heart Association classLeft ventricular outflow tract obstructionControl groupPresence of HCMBaseline functional classInternational multicentre registryVentricular systolic impairmentSevere clinical courseMulticentre registryNew onsetRespiratory failureAdverse eventsICU careAssociation class
Academic Achievements and Community Involvement
activity Section of Cardiovascular Disease Fellowship Training Program
CommitteesMemberDetailsParticipate in candidate interview and selection process2010 - Presentactivity Pediatric Cardiology Chief Search Committee
CommitteesMemberDetailsReviewed candidate options. Interviewed candidates. Provided feedback and participated in debate and discussion in the selection of the Pediatric Cardiology Chief position.2011 - Presentactivity Quality Assurance and Process Improvement Committee Co-Chair
CommitteesCo-ChairDetailsReview regulatory and quality metrics. Guide program through regulatory visits. Identify and improve on existing program structure for growth, quality, and efficiency. Solicit input from faculty and staff regarding program function. Establish metrics for dashboard population and review. Supervise development of internal metrics dashboard. Report out to Yale New Haven Transplant Center Quality Assessment and Process Improvement meeting.02/01/2014 - Presentactivity Advanced Heart Failure Recipient Review Committee Co-Chair
CommitteesCo-ChairDetailsOrganize structure and process around recipient review for advanced heart failure therapies (left ventricular assist devices and heart transplant). Arbitrate and act as final decision maker with Co-Chair (Surgical Director of Advanced Heart Failure) regarding transplant listing and device implant decisions for patients brought up for consideration. Supervise nursing and coordinator staff in recipient evaluation. Review any and all issues that arise in the course of the week regarding transplant listed patients. Establish and maintain heart transplant and LVAD protocols and pathways.02/01/2014 - Presentactivity Clinical Operations Committee - Section of Cardiovascular Diseases
CommitteesMemberDetailsRepresent the Comprehensive Heart Failure Program contributing to Cardiovascular Disease Section initiatives and clinical operations planning. Participate in Section vision and mission discussions particularly regarding clinical operations and contribute meaningful, actionable plans and perspectives to support and grow the Section of Cardiovascular Diseases on behalf of the faculty, staff, and patients we serve.2018 - Present
Links & Media
Media
News
- September 19, 2022
Burg co-edits special issue in Health Psychology
- July 27, 2022
Uncovering New Approaches to a Common Inherited Heart Disorder
- December 07, 2021
Cognitive behavioral therapy for insomnia improves function in people with heart failure, Yale study finds
- August 16, 2021
Countdown to 2021 American Heart Association Scientific Sessions
Related Links